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Abstract
Investors have difficulty funding the life sciences because of the high risks involved in
research and development and commercialization of new products. Risk in the
biopharmaceutical industry is the result of scientific, regulatory and economic
uncertainty. The nature of the biopharmaceutical industry introduces many challenges.
Each of these challenges incorporates a measure of risk into drug development. The level
of understanding of technical success interdependencies has not been fully investigated.
These interdependencies (correlations) could lead to an overall greater risk to the
company's portfolio than previously expected. A better understanding of the risks that
lead to success or failure in drug development might encourage more investment in the
life sciences and specifically in the biopharmaceutical industry, and a greater awareness
of the correlations between risks and products might lead to more informed decision
making on a biopharmaceutical portfolio leading increased productivity. A dataset was
collected from Thomson Reuters. The dataset is the oncology portfolio from a
biopharmaceutical company, Genentech Inc. Logistic regression was used to determine if
any of the defined variables contributed to the success or failure of the oncology
products. The chi-square value was 7.738 with the degrees of freedom equal to 5 and
with a p-value of 0.17. Therefore, none of the variables significantly contributed to the
outcome. More research should be performed in this area in order to better understand the
risk in a biopharmaceutical portfolio.
Thesis Advisor: Fiona Murray, PhD
Title: Associate Professor of Technological Innovation,
Entrepreneurship, and Strategic Management
Thesis Advisor: Andrew W. Lo
Title: Harris & Harris Group Professor of Finance,
Director of the Laboratory for Financial Engineering
Acknowledgements
I would like to thank the following people for supporting the completion of this thesis.
Without them, this work would never have happened. Thank you.
Professor Lo and Professor Murray for advising me.
The people who invest in healthcare and who work in the healthcare field for devoting
their lives to the betterment of mankind.
My friends in BEP - Jonathan Alspaugh, Alan Braly, Josh Gottlieb and Julie Hermann -
for brainstorming ideas and for sharing in the frustrations and joys over the last three
years.
David Pelly for his different way of thinking about the analytics.
My family for supporting every decision I have ever made and for providing me with
unconditional love.
Table of Contents
Abstract 2
Acknowledgements 3
Table of Contents 4
List of Figures 5
List of Tables 6
Chapter 1: Investing in Life Sciences 7
Chapter 2: Biologic Basis of Disease 24
Chapter 3: Formulating the Thesis 45
Chapter 4: Methodology 48
Chapter 5: Results 57
Chapter 6: Discussion 60
Bibliography 63
Appendix 65
List of Figures
Figure 1: Investors' Expectations for the Biopharma Industry 7
Figure 2: Cambridge Associates Study: Cumulative Venture Returns 15
Figure 3: Stages of Drug Development 18
List of Tables
Table 1: NIH Extramural Awards 8-11
Table 2: Summary of Pathways, Human Oncogenes & Tumor Suppressor Genes 28-32
Table 3: FDA Approved Drugs for Oncology 36-44
Table 4: Raw Number, Normalization and Delta Calculation for Ind. Variables 58
Chapter 1: Investing in the Life Sciences
History of Life Science Investing
The biopharmaceutical ecosystem is comprised of a complex web of interdependent
organizations. These include drug development organizations such as universities, the
National Institute of Health (NIH), Research and Development (R&D boutiques,
established biopharmaceutical companies, and health care providers, and investment
organizations such as governments, non-profits, angel funds, venture capital firms,
private equity firms and pension funds.
Investors have reevaluated their beliefs about the efficiency of biopharmaceutical's
innovation engine - and hence about the entire future value of the industry. Figure 1
shows the steady decline of the industry's price-to-earnings (P/E) ratio, a measure of
investor confidence in future profit growth.'
Figure 1: Investors' Expectations for the Biopharma Industry
Exhibit 1. Investors' Expectations for the Biopharrna
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Public Funding in the Life Sciences
The major source of public funding in the life sciences in the United States (US) is from
the National Institute of Health (NIH). The NIH invests over $31.2 billion annually in
medical research. More than 80% of the NIH's funding is awarded through almost 50,000
competitive grants to more than 325,000 researchers at over 3,000 universities, medical
schools, and other research institutions in every state and around the world. About 10%
of the NIH's budget supports projects conducted by nearly 6,000 scientists in its own
laboratories, most of which are on the NIH campus in Bethesda, Maryland 2. Table 1
shows the allocation of NIH extramural awards from 2001-2010.
Table 1: NIH Extramural Awardsa
Number of Awards and Organizations Funded by Organization Type
Fiscal Years* 2001-2010
Migner taucation 516 36,277 $12,278,336,624
2001 Research Institutes 200 3,437 $1,641,875,390
2001 Independent Hospitals 140 3,585 $1,301,412,303
2001 Other Domestic Nonprofit 305 984 $398,819,432
2001 Domestic For-Profit 1,287 2,180 $1,082,546,743
Foreign (includes all institution
2001 types listed above) 165 368 $77,864,500
2001
2002 Research Institutes 205 3,669 $1,825,220,560
2002 Independent Hospitals 140 3,774 $1,458,491,086
2002 Other Domestic Nonprofit 312 1,068 $490,742,491
2002 Domestic For-Profit 1,420 2,373 $1,276,015,658
Foreign (includes all institution
2002 types listed above) 223 471 $119,970,107
2003 Higher Education 534 40,516 $15,665,006,383
2003 Research Institutes 208 3,889 $2,085,466,889
2003 Independent Hospitals 138 3,750 $1,547,434,901
2003 Other Domestic Nonprofit 330 1,184 $556,865,509
2003 Domestic For-Profit 1,600 2,700 $1,814,251,570
Foreign (includes all institution
2003 types listed above) 273 548 $197,773,159
2004 Higher Education 5 32 4 1,55 4 , $16,102,526,149
2004 Research Institutes 210 3,897 $2,183,670,516
2004 Independent Hospitals 124 3,842 $1,611,238,994
2004 Other Domestic Nonprofit 338 1,245 $595,596,475
2004 Domestic For-Profit 1,684 2,880 $2,054,962,258
Foreign (includes all institution
2004 types listed above) 294 603 $352,582,195
2005 Higher Education 535 41,570 $16,688,059,009
2005 Research Institutes 211 3,924 $2,158,045,271
2005 Independent Hospitals 117 3,993 $1,708,661,086
Higher Education 515 38,361 $13,904,024,894
2005 Other Domestic Nonprofit 373 1,263 $546,051,495
2005 Domestic For-Profit 1,851 3,022 $2,025,019,484
Foreign (includes all institution
2005 types listed above) 333 793 $284,337,954
2006 Higher Education 542 41,479 $16,367,084,439
2006 Research Institutes 207 3,914 $2,193,172,719
2006 Independent Hospitals 116 4,014 $1,731,033,176
2006 Other Domestic Nonprofit 379 1,222 $532,030,211
2006 Domestic For-Profit 1,878 4,060 $2,066,408,275
Foreign (includes all institution
2006 types listed above) 327 744 $293,231,098
2006 TOAL. 3A49 55A33 $23.182.959918
2007 Higher Education 532 41,767 $16,801,934,311
2007 Research Institutes 200 3,812 $2,104,988,996
2007 Independent Hospitals 108 3,936 $1,763,529,298
2007 Other Domestic Nonprofit 346 1,185 $615,363,140
2007 Domestic For-Profit 1,634 2,688 $2,008,682,906
Foreign (includes all institution
2007
types listed above) 315 643 $206,892,687
2008 Higher Education 524 41,110 $16,779,594,423
2008 Research Institutes 203 3,656 $2,134,144,227
2008 Independent Hospitals 101 3,899 $1,731,243,120
2008 Other Domestic Nonprofit 325 1,096 $481,153,827
2008 Domestic For-Profit 1,385 2,310 $2,088,855,788
2008
Foreign (includes all institution
types listed above) $277,239,785
2005 t r o estic Nonprofit 373 1,263 $546,051,495
666 1
2009 Research Institutes 196 3,458 $2,185,767,859
2009 Independent Hospitals 96 3,744 $1,727,540,656
2009 Other Domestic Nonprofit 308 1,084 $605,253,735
2009 Domestic For-Profit 1,374 2,264 $2,390,424,600
Foreign (includes all institution
2009
types listed above) 288 616 $282,331,162
2010 Higher Education 478 39,951 $16,953,363,969
2010 Research Institutes 185 3,327 $1,941,045,871
2010 Independent Hospitals 89 3,760 $1,751,914,669
2010 Other Domestic Nonprofit 251 1,017 $522,949,207
2010 Domestic For-Profit 1,247 1,867 $853,818,657
Foreign (includes all institution
2010
types listed above) 516 $211,465,105
"NIH Awards Includes all grants and contracts except 2010 for which contract data is not included.
bNumber of Awards The number of awards is intended to show the number of unique projects funded. Therefore, for
grants, the number of noncompeting supplements is not included in the number of awards
because these supplements support existing projects, without expanding the scope of work.
However, the award amounts for noncompeting supplements are included in the award amount,
because they reflect total expenditures on funded projects. In contrast, the number of competing
supplements is included in the number of awards because these supplements represent expanded
scope of work on existing projects; the award amounts for competing supplements are also
included in the award amount. Similarly, for contracts, the number of noncompeting modifications
is not included in the number of awards because these modifications support existing projects,
without expanding the scope of work. The award amounts for noncompeting modifications are
included in the award amount, because they reflect total expenditures on funded projects.
Total funding is the funding amount for each fiscal year, and not for the life of the project.
Includes only awards made with Direct Budget Authority, Superfund Budget Authority and
Reimbursable funds.
*Due to the use of more refined analysis techniques, some pre-2009 data previously published has been updated in this table.
Data drawn from frozen FY 2010 Pub file as of 12/08/2010.
'Total Funding
Private Funding in the Life Sciences
Investing in the life sciences through private methods typically involves one or a
combination of the following vehicles: angel funds, venture capital funds, private equity
funds, pension funds, or established biopharmaceutical companies.
There are a number of funding stages that typically describe the maturity of a company.
Seed stage financing is a small initial investment, usually under $1 million, used to
validate a concept, get a company formed and complete the initial business plan. Series
A/B financing is one or two early rounds, roughly $1-5 million for Series A and $6- 10
million for Series B, that are typically venture capital financed. Series C/D financing are
possible financing rounds, generally $15-50 million, intended to take a company through
an exit. Mezzanine financing is classically the last financing round and the size depends
upon the needs of the company before the exit. A company might require bridge
financing before the completion of another round of financing or before an IPO to tie
them over. Finally, a buyout occurs when a company is purchased by venture capital firm
or investor group, after which the incumbent and/or incoming management will be given
3
or acquire a large stake in the business .
Angel Investors
An angel investor or angel (also known as a business angel or informal investor) is an
affluent individual who provides capital for a business start-up, usually in exchange for
convertible debt or ownership equity. A small but increasing number of angel investors
organize themselves into angel groups or angel networks to share research and pool their
12
investment capital4 .
Angel capital fills the gap in start-up financing between "friends and family" who provide
seed funding, and venture capital. Angel investments bear extremely high risk and are
usually subject to dilution from future investment rounds. As such, they require a very
high return on investment5 . Since a large percentage of angel investments are lost
completely when early stage companies fail, professional angel investors seek
investments that have the potential to return at least 10 or more times their original
investment within 5 years, through a defined exit strategy. According to the Center for
Venture Research, there were 258,000 active angel investors in the US in 2007 6. The past
few years, particularly in North America, have seen the emergence of networks of angel
groups, through which companies that apply for funding to one group are then brought
before other groups to raise additional capital7.
Venture Capital
Money provided by investors to startup firms and small businesses with perceived long-
term growth potential. This is a very important source of funding for startups that do not
have access to capital markets. It typically entails high risk for the investor, but it has the
potential for above-average returns.
Venture capitalists are often wary of investing in biotechnology because bioentrepreneurs
seldom provide realistic estimates of the value of their technologies9 . Investing in
healthcare has a higher bar than investing in other industries. Mike Carusi of Advanced
Technology Ventures states, "A lot of biotech firms can't get there. First off, they take
too long. Second, you have to invest too much money before you know you actually have
something. And finally, the technology risk is too high. Only one out of 10 drugs makes
it through to final approval."10
Not all VC firms even invest in health care. Investors do not get the same absolute return
in dollars on the health care that you do on telecoms or the Internet. "In venture capital,
the health care only firms are the ones that might invest in early-stage biotech
(therapeutics, i.e. drug development) companies, while a balanced fund like ourselves
won't," says Mike Carusi.' 0
Pension funds contribute to over 50% of US venture funds". Outside investors will put
money into venture funds only if they expect returns (IRR) to be greater than the cost of
capital. According to a study performed by Cambridge Associates covering 1606
biotechnology companies from 1986-2008, venture investment resulted in an average
gross IRR on realized biopharmaceutical investments of 20.7%, after fees and other costs
(5%). However, this came at huge risks. Of those investments, 44% were a full or partial
loss (Figure 2), two-thirds of the profitable investments took 5 years or more to be
realized, and over 1200 data points had yet to pay out by December 31, 2008.
Figure 2: Cambridge Associates Study: Cumulative Venture Returns
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Risks in Investing in the Life Sciences
Investors have difficulty funding the life sciences because of the high risks involved in
research and development and commercialization of new products. These risks include
high cost of capital, technical uncertainty (fewer than 1% of drug candidates will make it
to market), regulatory uncertainty, long time lines (typically 10 years or more) and many
others.
Risk in the biopharmaceutical industry is the result of scientific, regulatory and economic
uncertainty. The first two risks create the lengthy development time and thereby the
economic risk. The longer the scientific development time, the greater the likelihood that
a competitor will make the discovery first and thereby greatly diminish the possibility for
a return on the R&D investment of the innovator. Regulatory uncertainty occurs because
15
the time required for new drug approval further delays product marketing, and because
marketing approval is not assured".
Cost of capital
Investments in R&D are delivering diminished returns. A mere five years ago, industry
executives could expect every dollar invested in discovering new therapeutics to yield a
risk-adjusted return of 15% or more. Yet today, despite a wealth of new scientific
discoveries, returns on R&D in biopharmaceuticals have fallen to 11% or less, a rate
barely covering the cost of capital1 .
Evidence shows that the cost of capital for venture backed early stage companies in life
sciences is high (many estimates suggest 20% or higher). This reflects investors'
expectation of a return sufficient to compensate them for taking on extraordinary risk.
The cost of capital is a critical benchmark for assessing commercial viability of a project;
it measures the opportunity cost of resources, it is often used as the hurdle rate of return
to decide whether to invest, and it is also used as a discount rate to evaluate future cash
flows. Outside investors will put money into venture funds only if they expect returns
(IRR) to be greater than the cost of capital.
Technical Uncertainty
The concept of technical uncertainty is borrowed from Robert Pindyck. Technical
uncertainty arises from the physical difficulty of completing an R&D project. At the
origination of the project, limited information is available regarding the efforts, resources
and time required to successfully realize the future return. Initiating the project and
completing successive stages will incrementally reveal information related to these
issues. As the investment proceeds, the barriers to completion may become higher or
lower, but the true cost of the investment is only known with certainty once the projected
has reached completion. Thus, the "information revealing" nature of the technical
14uncertainty enhances the incentives to commence investment
There are several components to technical risk. A breakdown might look like:
o Known technical risks: safety (toxicity), efficacy, basic mechanism of
action (same target), clinical trial endpoint selection
o Unknown natural (potentially correlated) risks: dose-response relationship,
biomarkers for target, biomarkers for dose, established standard of care
Each stage of drug development has its own risks that role up into the total risk profile for
a given R&D project. The phases of drug development are portrayed in Figure 3.
Figure 3: Stages of Drug Development 5
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Below is a description of each stage of drug development.
Preclinical stage:
This stage comprises of study on animals to find out various parameters for a drug under
development. During preclinical drug development, a sponsor evaluates the drug's toxic
and pharmacological effects through in vitro and in vivo laboratory animal testing.
Genotoxicity screening is performed, as well as investigations on drug absorption and
metabolism, the toxicity of the drug's metabolites, and the speed with which the drug and
its metabolites are excreted from the body. At the preclinical stage, the Food & Drug
Esa
Administration (FDA) will generally ask, at a minimum, that sponsors: (1) develop a
pharmacological profile of the drug; (2) determine the acute toxicity of the drug in at
least two species of animals, and (3) conduct short-term toxicity studies ranging from 2
weeks to 3 months, depending on the proposed duration of use of the substance in the
proposed clinical studies 6
Clinical Stages:
Phase I: Phase I studies are carried out in healthy volunteers, which are small in number
- usually 20 to 100. The purpose of phase I studies is to identify metabolic and
pharmacological effects of drug in humans and to determine the side effects associated
with increasing doses, and, if possible, to gain early evidence on effectiveness. During
Phase 1, sufficient information about the drug's pharmacokinetics and pharmacological
effects is required. The purpose of phase I studies is to mainly determine safety profile'6 .
Phase II: Phase 2 includes the early controlled clinical studies conducted to obtain some
preliminary data on the effectiveness of the drug for a particular indication or indications
in patients with the disease or condition. This phase of testing also helps determine the
common short-term side effects and risks associated with the drug. Phase 2 studies are
typically well-controlled, closely monitored, and conducted in a relatively small number
of patients, usually involving several hundred people'6 .
Phase III: Phase 3 studies are expanded controlled and uncontrolled trials. They are
performed after preliminary evidence suggesting effectiveness of the drug has been
obtained in Phase 2, and are intended to gather the additional information about
effectiveness and safety that is needed to evaluate the overall benefit-risk relationship of
the drug. Phase 3 studies also provide an adequate basis for extrapolating the results to
the general population and transmitting that information in the physician labeling. Phase
3 studies usually include several hundred to several thousand people 16
Phase IV: In addition to these three phases, Phase IV, also known as Post Marketing
Surveillance is also carried out once the drug is approved and marketed. The aim of
Phase IV is to find out safety profile in large patient pool across the world and to
establish the safety profile of the drug. It is estimated that success rate of drugs making to
market from lab is very less. One drug, from among the thousands tested, makes it to the
market' 6.
One can think of the technical risk as a series of wagers. Clinical drug development
should be regarded as a series of high-risk wagers where success in the first wager (e.g. a
phase I trial) allows a company to make additional wagers (e.g. phase II and phase III
trials) before reaching the ultimate payoff (e.g. a marketed drug)9 .
The largest share of R&D spend by The Pharmaceutical Research and Manufacturers of
America (PhRMA) members is in the Phase III and prehuman/preclinical trials. Over
20% of drug failures in drug development have been attributed to toxicity concerns. The
20
application of genomic technologies, such as biomarkers, offers the opportunity to save
up to 34% of R&D costs17.
Regulatory Uncertainty
The concept of regulatory uncertainty is also borrowed from Pindyck. Regulatory
uncertainty arises from unpredictable aspects of the regulatory regime governing the
completion of the R&D program, which may take the form of unpredictable compliance
costs incurred over the course of the R&D project. The level of these costs may be higher
or lower depending on how regulators respond to factors such as public opinion or safety
concerns. In contrast to technical uncertainty, information about the regulatory regime
proceeds regardless of whether or not the firm is investing. This tends to have a
dampening effect on investment incentives, since the firm may benefit from delaying
investments in order to observe the regulatory regime and thus obtain more information
about its future trajectory".
The FDA has strict regulations involving laboratories, manufacturing, and clinical trials.
The Code of Federal Regulations provides a detailed list of all of the rules that must be
followed when developing a drug, biologic or device 15 . Adhering to these regulations
involves substantial costs that must be factored into the investment decision.
Long timelines
Development times have increased over the last decade, which is largely due to drugs
becoming more innovative and subsequently requiring more testing and developing
17compared to less novel drugs with familiar mechanisms of action"
Other risks
Getting a drug on the market is no longer just a matter of proving its clinical efficacy - a
company must now prove the product's cost effectiveness as well'. Decisions about
which health-care interventions represent adequate value to collectively funded health-
care systems are as widespread as they are unavoidable. In the case of new
biopharmaceuticals, many countries now require formal cost-effectiveness analysis to
inform this decision-making process. This requires evidence on parameters associated
with health-related utilities, treatment effects, resource use, and costs, for which data
from available regulatory trials are invariably absent or highly uncertain. This uncertainty
results from a number of factors including the predominance of intermediate end points
in the clinical evidence-base and the limited period of follow-up of patients in clinical
studies.
Despite these imperfections in the evidence base, decisions about whether new
pharmaceuticals are sufficiently cost-effective for reimbursement cannot be side-stepped.
Data limitations do, however, require the use of rigorous analytical methods to support
decision making. Probabilistic decision models and value of information analysis offer a
means of structuring decision problems, synthesizing all available data, characterizing the
22
uncertainty in the decision, quantifying the cost of uncertainty, and establishing the
expected value of perfect information.
This analytical framework is important because it addresses two fundamental questions
about new pharmaceuticals. First, is the product expected to be cost-effective on the basis
of existing evidence? Second, is additional research concerning the product itself cost-
effective? In addressing these questions, the analytical framework can establish when
sufficient evidence exists to sustain a claim for a new pharmaceutical to be cost-
effective'8
Chapter 2: Biologic Basis of Disease - Oncology
Oncology Overview
Cancer is an abnormal growth of cells. Cancer cells rapidly reproduce despite restriction
of space, nutrients shared by other cells, or signals sent from the body to stop
reproduction. Cancer cells are often shaped differently from healthy cells, they do not
function properly, and they can spread to many areas of the body. Tumors, abnormal
growth of tissue, are clusters of cells that are capable of growing and dividing
uncontrollably; their growth is not regulated.
Oncology is the study of cancer and tumors. The term "cancer" is used when a tumor is
malignant, which is to say it has the potential to cause harm, including death. Tumors can
be benign (noncancerous) or malignant (cancerous). Benign tumors tend to grow slowly
and do not spread. Malignant tumors can grow rapidly, invade and destroy nearby normal
tissues, and spread throughout the body. The original tumor is called the "primary
tumor." Its cells, which travel through the body, can begin the formation of new tumors
in other organs. These new tumors are referred to as "secondary tumors."
Cancer is not just one disease but rather a group of diseases, all of which cause cells in
the body to change and grow out of control. Cancers are classified either according to the
kind of fluid or tissue from which they originate, or according to the location in the body
where they first developed. In addition, some cancers are of mixed types.
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The following five broad categories indicate the tissue and blood classifications of
cancer:
Carcinoma: A carcinoma is a cancer found in body tissue known as epithelial tissue that
covers or lines surfaces of organs, glands, or body structures. For example, a cancer of
the lining of the stomach is called a carcinoma. Many carcinomas affect organs or glands
that are involved with secretion, such as breasts that produce milk. Carcinomas account
for 80 percent to 90 percent of all cancer cases.
Sarcoma: A sarcoma is a malignant tumor growing from connective tissues, such as
cartilage, fat, muscle, tendons, and bones. The most common sarcoma, a tumor on the
bone, usually occurs in young adults. Examples of sarcoma include osteosarcoma (bone)
and chondrosarcoma (cartilage).
Lymphoma: Lymphoma refers to a cancer that originates in the nodes or glands of the
lymphatic system, whose job it is to produce white blood cells and clean body fluids, or
in organs such as the brain and breast. Lymphomas are classified into two categories:
Hodgkin's lymphoma and non-Hodgkin's lymphoma.
Leukemia: Leukemia, also known as blood cancer, is a cancer of the bone marrow that
keeps the marrow from producing normal red and white blood cells and platelets. White
blood cells are needed to resist infection. Red blood cells are needed to prevent anemia.
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Platelets keep the body from easily bruising and bleeding. Examples of leukemia include
acute myelogenous leukemia, chronic myelogenous leukemia, acute lymphocytic
leukemia, and chronic lymphocytic leukemia. The terms myelogenous and lymphocytic
indicate the type of cells that are involved.
Myeloma: Myeloma grows in the plasma cells of bone marrow. In some cases, the
myeloma cells collect in one bone and form a single tumor, called a plasmacytoma.
However, in other cases, the myeloma cells collect in many bones, forming many bone
tumors. This is called multiple myeloma.
There is no one single cause for cancer. Scientists believe that it is the interaction of
many factors together that produces cancer. The factors involved may be genetic,
environmental, or constitutional characteristics of the individual.
Diagnosis, treatment, and prognosis for childhood cancers are different than for adult
cancers. The main differences are the survival rate and the cause of the cancer. The
survival rate for childhood cancer is about 75 percent, while in adult cancers the survival
rate is 60 percent. This difference is thought to be because childhood cancer is more
responsive to therapy, and a child can tolerate more aggressive therapy.
Childhood cancers often occur or begin in the stem cells, which are simple cells capable
of producing other types of specialized cells that the body needs. A sporadic (occurs by
chance) cell change or mutation is usually what causes childhood cancer.
In adults, the type of cell that becomes cancerous is usually an "epithelial" cell, which is
one of the cells that line the body cavity, including the surfaces of organs, glands, or body
structures, and cover the body surface. Cancer in adults usually occurs from
environmental exposures to these cells over time. Adult cancers are sometimes referred to
as "acquired" for this reason.
The discovery of certain types of genes that contribute to cancer has been an extremely
important development for cancer research. Over 90 percent of cancers are observed to
have some type of genetic alteration. A small percentage (5 percent to 10 percent) of
these alterations are inherited, while the rest are sporadic, which means they occur by
chance or occur from environmental exposures (usually over many years).
There are three main types of genes that can affect cell growth, and are altered (mutated)
in certain types of cancers, including the following:
Oncogenes: These genes regulate the normal growth of cells. Scientists commonly
describe oncogenes as similar to a cancer "switch" that most people have in their bodies.
What "flips the switch" to make these oncogenes suddenly become unable to control the
normal growth of cells and allowing abnormal cancer cells to begin to grow, is unknown.
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Tumor suppressor genes: These genes are able to recognize abnormal growth and
reproduction of damaged cells, or cancer cells, and can interrupt their reproduction until
the defect is corrected. If the tumor suppressor genes are mutated, however, and they do
not function properly, tumor growth may occur.
Mismatch-repair genes: These genes help recognize errors when DNA is copied to
make a new cell. If the DNA does not "match" perfectly, these genes repair the mismatch
and correct the error. If these genes are not working properly, however, errors in DNA
can be transmitted to new cells, causing them to be damaged.
Usually the number of cells in any of our body tissues is tightly controlled so that new
cells are made for normal growth and development, as well as to replace dying cells.
Ultimately, cancer is a loss of this balance due to genetic alterations that "tip the balance"
in favor of excessive cell growth.
Pathways: Mechanisms ofAction
There are many different ways in which a cancer can form. Ten signaling pathways have
been identified, and multiple proteins are associated with each pathway. These proteins
are either oncogenes or tumor suppressor genes. Characterization of these pathways has
led scientists to better understand the mechanisms of action by which a tumor can form.
The ten pathways with respective proteins and genetic alterations are listed in Table 2.
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Table 2: Summary of Pathways and Human Oncogenes & Tumor Suppressor Genes
PATHWAY PROTEIN ONCOGENE/ GENETIC CONFERRED
TUMOR ALTERATIONS CAPABILITIES
SUPPRESSORS
Oncogenes Point mutation, Self-sufficiency in
TGFp Myc
Amplification growth signals
Tumor Insensitivity to anti-
BMPR Point Mutation
Suppressors growth signals
Tumor Insensitivity to anti-
Smad 2/3 Point Mutation
Suppressors growth signals
Tumor Insensitivity to anti-
Smad 4 Point Mutation
Suppressors growth signals
Tumor Insensitivity to anti-
TGFP R Point Mutation
Suppressors growth signals
Oncogene Self-sufficiency in
Wnt B-catenin Point Mutation
growth signals
Oncogene Self-sufficiency in
RAR Amplification
growth signals
Oncogene Amplification, Self-sufficiency in
Sox
Increased expression growth signals
Oncogene Self-sufficiency in
Wntl Increased expression
growth signals
Tumor Self-sufficiency in
APC Point Mutation
Suppressors growth signals
Tumor Self-sufficiency in
Axin Point Mutation
Suppressors growth signals
Tumor Tissue invasion &
a-catenin Point Mutation
Suppressors metastasis
Tumor Self-sufficiency in
Suppressors growth signals,
E-cadherin Point Mutation Insensitivity to anti-
growth signals, Tissue
invasion & metastasis
Tumor Self-sufficiency in
Wnt5A Point Mutation
Suppressors growth signals
Oncogene Self-sufficiency in
GPCR Ga Point Mutation
growth signals
Oncogene Self-sufficiency in
GPCR Point Mutation
growth signals
Oncogene Self-sufficiency in
Ras P-Raf Point Mutation
growth signals
Oncogene Evading apoptosis,
Fos/Jun Increased expression Self-sufficiency in
growth signals
Oncogene Self-sufficiency in
ILK Increased expression growth signals, Tissue
invasion & metastasis
Oncogene Self-sufficiency in
Ras Point Mutation
growth signals
Oncogene Evading apoptosis,
Point Mutation,
Self-sufficiency in
Translocation,
RTKs growth signals, Tissue
Amplification,
invasion & metastasis,
Increased expression
Sustained angiogenesis
Tumor Tissue invasion &
Integrin Deletion
Suppressors metastasis
Tumor Point Mutation, Self-sufficiency in
NFl
Suppressors Deletion growth signals
Tumor
VHL Point Mutation Sustained angiogenesis
Suppressors
Oncogene Point Mutation,
Akt Akt Amplification, Increase Evading apoptosis
expression
Bax Oncogene Point Mutation Evading apoptosis
FKHR/FOXO Oncogene Translocation Evading apoptosis
Oncogene Evading apoptosis,
Point Mutation,
JAK Self-sufficiency in
Translocation
growth signals
P13K Oncogene Point Mutation Evading apoptosis
Tumor
Bcl-2 Translocation Evading apoptosis
Suppressors
Tumor Self-sufficiency in
LKBI Point Mutation
Suppressors growth signals
Tumor Point Mutation,
PTEN Evading apoptosis
Suppressors Deletion
Tumor Self-sufficiency in
TSC1/TSC2 Point Mutation
Suppressors growth signals
Death Receptor Fas Oncogene Point Mutation Evading apoptosis
Notch Notch Oncogene Translocation Evading apoptosis
Oncogene Evading apoptosis,
Amplification,
Hedgehog Gli Self-sufficiency in
Translocation
growth signals
Oncogene Evading apoptosis,
Hedgehog Point Mutation Self-sufficiency in
growth signals
Oncogene Evading apoptosis,
Smo Point Mutation
Self-sufficiency in
growth signals
Tumor Evading apoptosis,
Ptch Suppressors Point Mutation Self-sufficiency in
growth signals
Tumor Evading apoptosis,
Su(Fu) Suppressors Point Mutation Self-sufficiency in
growth signals
Oncogene Self-sufficiency in
Cell Cycle Ab Translocation
growth signals
Oncogene Amplification, Self-sufficiency in
CDK2
Increased expression growth signals
Oncogene Self-sufficiency in
CDK4 Point Mutation
growth signals
Oncogene Amplification, Self-sufficiency in
Cyclin D
Translocation growth signals
Oncogene Self-sufficiency in
Cyclin E Amplification
growth signals
Oncogene Self-sufficiency in
HPV-E6 Viral infection
growth signals
Tumor Self-sufficiency in
p 15 Point Mutation
Suppressors growth signals
Tumor Self-sufficiency in
p 16 Point Mutation
Suppressors growth signals
Tumor Self-sufficiency in
Rb Point Mutation
Suppressors growth signals
Oncogene Amplification, Self-sufficiency in
DNA Damage Aurora A
Increased expression growth signals
HPV-E6 Oncogene Viral infection Evading apoptosis
MDM2 Oncogene Amplification Evading apoptosis
Tumor Self-sufficiency in
ARF Point Mutation
Suppressors growth signals
Tumor Insensitivity to anti-
ATM/ATR Point Mutation
Suppressors growth signals
Tumor Self-sufficiency in
Suppressors growth signals,
BRCAI Point Mutation
Insensitivity to anti-
growth signals
Tumor Insensitivity to anti-
Chkl Point Mutation
Suppressors growth signals
Tumor Insensitivity to anti-
Chk2 Point Mutation
Suppressors growth signals
Tumor Insensitivity to anti-
DNA-PK Point Mutation
Suppressors growth signals
Tumor Insensitivity to anti-
FANCD2 Point Mutation
Suppressors growth signals
Tumor Evading apoptosis,
HIPK2 Suppressors Point Mutation Self-sufficiency in
growth signals
Tumor Point Mutation, Insensitivity to anti-
NBSI
Suppressors Deletion growth signals
Tumor Evading apoptosis,
Point Mutation,
p 53 Suppressors Insensitivity to anti-
Deletion
growth signals
Biomarkers in Cancer
Knowledge of the natural history of cancer progression has advanced in the past decade,
but has been limited in part by the technology available to detect it. Multiple, sequential,
parallel, and interconnected changes in cellular machinery over-ride normal biological
regulation, and lead to cells becoming neoplastic and invasive. If a cancer could be
detected at the incipient stage and its advance halted, we would be able to reduce the
mortality associated with the disease".
Biomarkers are cellular indicators of the physiological state and also of change during a
disease process. Active genes, their respective products, and other organic chemicals
made by the cell are unique identifiers that make up the 'molecular signature' of a cell. It
has been a challenge to detect these changes in signatures during the early stages of
transformation. The signatures may reflect genotoxicity, hyperproliferation, altered
patterns of gene expression, hyperplasia, inflammation, aberrant crypt foci, and
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enzymatic changes that are responses to inherited and environmental causes of cancer
Novel technologies increase our ability to investigate molecular mechanisms of
carcinogenesis and might enable us to overcome the challenges in early detection. In this
review, we focus on promising molecular signatures, the technologies being developed to
detect them, and issues concerning their usefulness 9 .
Identification and detection of cancer by pathological techniques are possible only on
microscopic examination of the tumor tissue, long after disease onset. Although these
techniques are important for prediction of tumor behavior and prognosis, additional
methods are necessary for early detection. The usefulness of a biomarker lies in its ability
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to provide early indication of disease or the progression of the disease. Biomarkers
should be easy to detect, measurable across populations, and amenable to use in one or
more of the following settings: detection at an early stage; identification of high-risk
individuals; early detection of recurrence; or as intermediate endpoints in
19
chemoprevention' .
Biomarkers of risk can help identify individuals who are at increased risk of developing
cancer, before the biological onset of the disease. These biomarkers are based mainly on
inherited or somatically acquired susceptibilities, in the form of altered genes such as
MSH2 and MLH in hereditary non-polyposis colorectal cancer, PRB in hereditary
retinoblastoma, and BRCA1 and BRCA2 mutated genes that predispose to breast cancer.
In these cases, there is an inherent familial predisposition to the development of some
type of cancer, although many individuals inheriting mutated genes will not develop
cancer. This suggests the involvement of other factors, such as the environment, which
could interact with specific genes to initiate cancer. However, risk markers are important
in monitoring of individuals and allow early intervention in those who do develop
19
cancer
Genetic inheritance accounts for only a small percentage of cancer incidence in the
general population. Biomarkers can detect the outcomes of interaction between genetic
susceptibility and the environment and are therefore extremely important for early
detection. Theoretically, they could provide the opportunity to intervene during the
natural progression of the cancer, to cause inhibition, regression, or even elimination of
the disease. After biological onset, the disease progresses through a preclinical phase
before symptoms develop; changes in biomarkers during this phase could be very helpful
in early detection, and research has focused on the discovery of biomarkers for this
stage 9.
Successful Cancer Products
Oncology products have historically been successful in gaining approval through the
FDA, mainly due to the large unmet need. The table (Table 3) below shows all the
oncology products approved by the FDA from 2000 to present.
Table 3: FDA Approved Drugs for Oncology20
BRAND NAME PRODUCT NAME COMPANY INDICATION APPROVAL DATE
Breakthrough cancer
Fentanyl sublingual
Abstral ProStraken pain in opioid-tolerant January 2011
tablets
patients
Advanced pancreatic
Afinitor Everolimus Novartis May 2011
neuroendocrine tumors
Management of
Lazanda Fentanyl citrate Archimedes breakthrough cancer June 2011
pain
Pancreatic
Sutent Sunitinib malate Pfizer May 2011
neuroendocrine tumors
Sylatron Peginterferon alfa-2b Merck Melanoma April 2011
Vandetanib
Vandetanib Astra Zeneca Thyroid cancer April 2011
Yervoy lpilimumab Bristol-Myers Metastatic melanoma March 2011
Squibb
Zytiga Abiraterone acetate Centocor Ortho Prostate cancer May 2011
Biotech
Metastatic breast
Halayen Eribulin mesylate Eisai cancer November 2010
Herceptin Trastuzumab Genentech Gastric cancer October 2010
Jevtana Cabazitaxel Sanofi Aventis Prostate cancer June 2010
Hormone refractory
Provenge Sipuleucel-T Dendreon prostate cancer May 2010
Prevention of skeletal-
related events in
Xgeva Denosumab Amgen patients with bone November 2010
metastases from solid
tumors
Prevention of post-
Ondansetron oral Strativa operative,
Zuplenz soluble film Pharmaceuticals chemotherapy and July 2010
radiotherapy induced
nausea and vomiting
Afinitor Everolimus Novartis . March 2009Renal cell carcinoma Mrh20
Arzerra Ofatumumab GlaxoSmithKline Chronic lymphocytic October 2009
leukemia
Avastin Bevacizumab Genentech Renal cell carcinoma July 2009
Human Papillomavirus Prevention of cervical
Bivalent (Types 16 & cancer and cervical
Cervarix GlaxoSmithKline . October 2009
18) Vaccine, intraepithelial
Recombinant neoplasia caused by
HPV types 16 and 18
Management of plasma
Elitek Rasburicase Sanofi Aventis uric acid levels in October 2009
adults with
malignancies
Allos
Folotyn Pralatrexate injection Peripheral T-cell September 2009
Therapeutics lymphoma
Gloucester
Istodax Romidepsin Cutaneous T-cell November 2009
Pharmaceuticals lymphoma
BioDelivery Management of
Onsolis Fentanyl buccal Sciences breakthrough cancer July 2009
pain
Vortrient Pazopanib GlaxoSmithKline Renal cell carcinoma October 2009
Ferring
Degarelix Degarelix for injection Pharmaceuticals Prostate cancer December 2008
Rescue after high-dose
Spectrum methotrexate therapy
Fusilev Levoleucovorin March 2008
Pharmaceuticals in osteosarcoma and to
reduce the toxicity of
methotrexate
Non-Hodgkin's
Mozobil Plerixafor injection Genzyme lymphoma and December 2008
multiple myeloma
Sancuso Granisetron ProStrakan Chemotherapy-induced September 2008
nausea and vomiting
Chronic lymphocytic
Bendamustine
Treanda Cephalon leukemia and B-cell October 2008
hydrochloride non-Hodgkin's
lymphoma
Treatment/prevention
of osteoporosis and
Raloxifene
Evista Eli Lilly reduction of breast September 2007
hydrochloride cancer risk in
postmenopausal
women
Topotecan
Hycamtin GlaxoSmithKline October 2007
hydrochloride Small cell lung cancer
Bristol-Myers
Ixempra Ixabepilone Squibb Breast cancer October 2007
Tasigna Nilotinib hydrochloride Novartis Chronic myelogenous October 2007
monohydrate leukemia
Torisel Temsirolimus Wyeth Renal cell carcinoma May 2007
Tykerb Lapatinib GlaxoSmithKline Breast cancer March 2007
Quadrivalent human
papillomavirus (types Prevention of cervical
Gardasil Merck .June 2006
6, 11, 16, 18) cancer associated with
recombinant vaccine human papillomavirus
Bristol-Myers
Sprycel Dasatinib Imatinib-resistant June 2006
Squibb
chronic myeloid
leukemia
Kidney cancer and
Sutent Sunitinib Pfizer gastrointestinal stromal January 2006
tumors
Vectibex Panitumumab Amgen Colorectal cancer September 2006
T-cell acute
lymphoblastic
Arranon Nelarabine GlaxoSmithKline . October 2005leukemia and T-cell
lymphoblastic
lymphoma
Nexavar Sorafenib Bayer/Onyx Renal Cell Carcinoma December 2005
Pemetrexed for
Alimta Eli Lilly Malignant pleural February 2004
injection mesothelioma
Avastin Bevacizumab Genentech Metastatic carcinoma February 2004
of the colon or rectum
Acute lymphoblastic
Clolar Clofarabine Genzyme leukemia in pedia c December 2004
patients
EGFR-expressing,
Erbitux Ceuximab Imclone metastatic colorectal February 2004
cancer
Secondary
hyperparathyroidism
Sensipar Cinacalcet Amgen and hy.rcalcemia in March 2004
parathyroid carcinoma
patients
Genentech/OSI
Tarceva Erlotinib Advanced refractory November 2004
Pharmaceuticals
metastatic non-small
cell lung cancer
Prevention of nausea
MGI
and vomiting
Aloxi Palonosetron Pharma/Helsinn associated with August 2003
Healthcare emetogenic cancer
chemotherapy
CD20 positive,
follicular, non-
Bexxar Corixa Hodgkin's lymphoma June 2003
following
chemotherapy relapse
Treatment of nausea
Emend Aprepitant Merck and vomiting March 2003
associated with
chemotherapy
Second-line treatment
Iressa Gefitinib Astra Zeneca of non-small-cell lung May 2003
cancer
Plenaxis Abarelix for injectable Praecis Advanced prostate December 2003
suspension Pharmaceuticals cancer
Prevention of
postmenopausal
Premarin Conjugated estrogens Wyeth osteoporosis and July 2003
treatment of vasomotor
menopause symptoms,
Alfuzosin HCI Signs and symptoms of
UroXatral Sanofi Aventis .June 2003
extended-release tablets benign prostatic
hyperplasia
Velcade Bortezomib Millennium May 2003
Multiple myeloma
Pharmaceuticals
patients who have
received at least two
prior therapies
Eloxatin Oxaliplatin/5- Sanofi Aventis Colon or rectum August 2002
fluorouracil/leucovorin) carcinomas
Atrix Palliative treatment of
Eligard Leuprolide acetate Laboratories advanced prostate January 2002
cancer
Hormone receptor
Faslodex Fulyestrant Astra Zeneca positive metastatic April 2002
breast cancer
Gastrointestinal
Gleevec Imatinib mesylate Novartis stromal tumors February 2002
(GISTs)
Treatment to decrease
the chance of infection
Neulasta Amgen by fbil . January 2002
in patients receiving
chemotherapy
To aid in the diagnosis
SecreFlo Secretin Repligen of pancreatic April 2002
dysfunction and
gastrinoma
Zevalin Ibritumomab tiuxetan Biogen Idec Non-Hodgkin's February 2002
lymphoma
Multiple myeloma and
Zometa Zoledronic acid Novartis bone metastases from February 2002
solid tumors
Campath Berlex May 2001
B-cell chronic
Laboratories
lymphocytic leukemia
First-line treatment of
postmenopausal
Femara Letrozole Novartis . January 2001
women with locally
advanced or metastatic
breast cancer
Gleevec Imatinib mesylate Novartis Chronic myeloid May 2001
leukemia
Prevention of nausea
Kytril Granisetron Roche and vomiting June 2001
associated with cancer
therapy
Trelstar LA Triptorelin pamoate Debiopharm Advanced stage June 2001
prostate cancer
Xeloda Roche Metastatic colorectal May 2001
cancer
Zometa Zoledronic acid Novartis Hypercalcemia of August 2001
malignancy
Gemtuzumab
Mylotarg Wyeth CD33 positive acute May 2000
ozogamicin mycloid leukemia
Debiopharm! Palliative treatment of
Trelstar Depot Triptorelin pamoate Target Research advanced prostate June 2000
Associates
cancer
Induction of remission
Cell and consolidation in
Trisenox Arsenic trioxide Therapeutics patients with acute September 2000
promyelocytic
leukemia
Even with the approval of these products, there is still a large unmet need in oncology,
and thus, biopharmaceutical companies continue to develop potential new cancer
treatments.
Leuprolide acetate Pain relief in men with
Viadur Alza March 2000
implant advanced prostate
cancer
Chapter 3: Formulating the thesis
The nature of the biopharmaceutical industry introduces many of the challenges
discussed above. Each of these challenges incorporates a measure of risk into drug
development. Additionally, innovation in technologies for target identification and
product screening, an increased number of investigational products in pipelines of
biopharmaceutical companies, limited resources for development of new products,
increasing costs in the development of new products and increasing uncertainty (risk) has
led to a need for portfolio management within medium to large biopharmaceutical
companies. Managing the new product pipeline is a series of trade- offs among
maximizing expected economic returns, minimizing risk, and maintaining diversity in the
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product mix for a given level of renewable and nonrenewable corporate resources
A look at the history of portfolio management within the biopharmaceutical industry has
revealed many attempts at solving the problem of portfolio management by trying to
increase efficiency and improve results, but to date it has not been successful. Many
different methods have been used: decision trees, real option valuation, Monte Carlo, and
discounted cash flow (DCF). An understanding of the interdependencies within the
industry might help to better understand the risks21. Four groups of interdependencies
within the biopharmaceutical industry have been identified:
Resource dependencies - Example: learning curves lead to decreased development
times for similar drugs types
Manufacturing costs dependencies - Example: use of the same facilities for 2 products
Financial return dependencies - Example: cannibalization or complementation
Technical success dependencies - Example: technical success or failure of a drug
candidate affects the probability of technical success of an as-yet-untested trailing drug
candidate2 1
The level of understanding of technical success interdependencies has not been fully
investigated. These interdependencies (correlations) could lead to an overall greater risk
to the company's portfolio than previously expected.
Recently, the financial industry has begun to define the systemic risk inherent in hedge
funds and markets. This leads one to ask the question: can one use methods of portfolio
management and evaluation of risks within finance and apply to the biopharmaceutical
industry?
Correlated risk is risk that entails high correlation of markets as well as the degree to
which different markets are interconnected. The higher the correlation there is in different
markets the greater chance there is for systemic market failure. Since diversifying your
investment portfolio with different stocks cannot save you from systemic market failure
you have to know how to hedge your bets. Essentially, markets that are negatively
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correlated and are fundamentally counteracting each other are the best markets to balance
an entire investment portfolio. Does the same methodology apply to biopharmaceutical
portfolios? Is it possible to identify the risks that lead to success or failure in drug
development, and is it possible to understand the relationships between those risks that
might underlie correlations between products?
A better understanding of the risks that lead to success or failure in drug development
might encourage more investment in the life sciences and specifically in the
biopharmaceutical industry, and a greater awareness of the correlations between risks and
products might lead to more informed decision making on a biopharmaceutical portfolio
leading increased productivity.
Chapter 4: Methodology
Collecting the data
A dataset was collected from Thomson Reuters. The dataset is the oncology portfolio
from a biopharmaceutical company, Genentech Inc. The information collected through
this data source were the product's:
* Highest development status (i.e. discovery through launched)
* Therapeutic area
* Mechanism of action
* Target
- Type of technology (e.g. small molecule or biologic)
For purposes of this analysis, all products still in discovery were excluded because the
risk factors are very different than clinical stage products and there are fewer publications
on those risks.
The remainder of the data was collected through literature research. Potential and known
risks factors were identified. These risk factors were narrowed down to the following:
* Expected return
e Established mechanisms of action
e Proven animal model
* Available biomarker for disease (identified at FDA approval)
* Available biomarker for dosing (identified at FDA approval)
* Companion diagnostic developed (approval with product)
* Established endpoints for primary indication
* FDA prior experience with primary indication
* FDA prior experience with mechanism of action (pathway)
* Reimbursement potential
* Established standard of care for primary indication
- Presence of dose-response relationship
The assumptions for each of these risk factors are as follows:
* Therapeutic area: for those products without a primary indication specified, a
generic term "cancer" was used. For purposes of estimating the market size for
"cancer," an average incidence per type of cancer was used. This data was
collected from the American Cancer Society. For those products with "solid
tumor" specified for therapeutic area, the same approach was used for estimating
market size.
* Expected return: For launched products, cumulative sales to date were collected
from company financial statements and rounded to the nearest million. For
products still in development, the following assumptions were build into the
forecasted expected return: 7 years of market exclusivity, 30% market
penetration, 3 years to peak sales, 10% discount rate and pricing based on an
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average of oral oncology products (source: pharmacytimes.com, "Oral Oncology
Therapies: Specialty Pharmacy's Newest Challenge). The market size used for
those products with the generic "cancer" was an average of all cancer cases taken
from the American Cancer Society 2011 statistics.
* Established mechanisms of action: if information could not be found through a
literature search, then it was assumed that a mechanism of action was not
established.
- Proven animal model: if a mechanism of action is not established, then it was
assumed that an animal model was not proven. Additionally, if information could
not be found through a literature search, then it was assumed that an animal model
was not proven.
- Available biomarker for disease (identified at FDA approval): if information
could not be found through a literature search, then it was assumed that a disease
biomarker was not available.
* Available biomarker for dosing (identified at FDA approval): if information could
not be found through a literature search, then it was assumed that a dosing
biomarker was not available.
e Companion diagnostic developed (approved with product): if information could
not be found through either clinicaltrials.gov or company website, then it was
assumed that a companion diagnostic was not in co-development.
e Established endpoints for primary indication: endpoints were considered
established if an FDA guidance exists
* FDA prior experience with primary indication: it was assumed that the FDA had
prior experience with a disease area if a guidance was provided or if another drug
product has been approved.
* FDA prior experience with mechanism of action (pathway): it was assumed that
the FDA had prior experience with a biological pathway if a guidance was
provided or if another drug product has been approved with the same mechanism
of action.
Reimbursement potential: it was assumed that all products would be reimbursed
due to the unmet need in oncology therapies.
- Established standard of care for primary indication: if information could not be
found through a literature search, then it was assumed that a standard of care was
not established.
- Presence of dose-response relationship: if information could not be found through
a literature search, then it was assumed that a dose-response relationship was not
present.
Analysis
The first step of the analysis is to observe the data for any variables that resulted in the
same value for all outcomes, success and failure, and to remove those variables from the
dataset. For example, if all products, regardless of success or failure, in the dataset had
the same value for an independent variable, that independent variable should be removed
from the analysis. This is done because those variables will not contribute to the
regression model or the overall outcome.
The second step of the analysis is to count the raw number of outcomes for each
independent variable by the overall outcome of success or failure. Then, by normalizing
these raw values and calculating the delta between those normalized percentages for
successes and failures, one can eliminate other independent variables that will not have
large contributions to regression model. The idea in eliminating independent variables
that will not largely contribute is to ultimately build a regression model that only contains
variables that are significant to the outcome.
Logistic regression is part of a category of statistical models called generalized linear
models. Logistic regression allows one to predict a discrete outcome from a set of
variables that may be continuous, discrete, dichotomous, or a mix of any of these.
Generally, the dependent variable is dichotomous, such as success/failure. In instances
where the independent variables are a categorical, or a mix of continuous and categorical,
logistic regression is used.
The dependent variable in logistic regression is usually dichotomous; that is, the
dependent variable can take the value 1 with a probability of success q, or the value 0
with probability of failure 1 -q. This type of variable is called a Bernoulli (or binary)
variable. As mentioned previously, the independent or predictor variables in logistic
regression can take any form. That is, logistic regression makes no assumption about the
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distribution of the independent variables. They do not have to be normally distributed,
linearly related or of equal variance within each group. The relationship between the
predictor and response variables is not a linear function in logistic regression; instead, the
logistic regression function is used, which is the logit transformation of q:
1+ e (a+61X1+IAX2++I-+x
Where a is equal to the constant of the equation and b is equal to the coefficient of the
predictor variables. The goal of logistic regression is to correctly predict the category of
outcome for individual cases using the tightest model. To accomplish this goal, a model
is created that includes all predictor variables that are useful in predicting the response
variable. Several different options are available during model creation. Variables can be
entered into the model in the order specified by the researcher or logistic regression can
test the fit of the model after each coefficient is added or deleted, called stepwise
regression.
Stepwise regression is used in the exploratory phase of research but it is not
recommended for theory testing (Menard 1995). Theory testing is the testing of a-priori
theories or hypotheses of the relationships between variables. Exploratory testing makes
no a-priori assumptions regarding the relationships between the variables; thus the goal is
to discover relationships.
Backward stepwise regression appears to be the preferred method of exploratory
analyses, where the analysis begins with a full or saturated model and variables are
eliminated from the model in an iterative process. The fit of the model is tested after the
elimination of each variable to ensure that the model still adequately fits the data. When
no more variables can be eliminated from the model, the analysis has been completed.
For this analysis, backward stepwise regression was used.
There are two main uses of logistic regression. The first is the prediction of group
membership. Since logistic regression calculates the probability or success over the
probability of failure, the results of the analysis are in the form of an odds ratio. For
example, logistic regression is often used in epidemiological studies where the result of
the analysis is the probability of developing cancer after controlling for other associated
risks. Logistic regression also provides knowledge of the relationships and strengths
among the variables (e.g., smoking 10 packs a day puts you at a higher risk for
developing cancer than working in an asbestos mine).
The process by which coefficients are tested for significance for inclusion or elimination
from the model involves several different techniques. The first is the Wald test. A Wald
test is used to test the statistical significance of each coefficient (b) in the model. A Wald
test calculates a Z statistic, which is:
BZ=
SE
This z value is then squared, yielding a Wald statistic with a chi-square distribution.
However, several authors have identified problems with the use of the Wald statistic.
Menard (1995) warns that for large coefficients, standard error is inflated, lowering the
Wald statistic (chi-square) value. Agresti (1996) states that the likelihood-ratio test is
more reliable for small sample sizes than the Wald test. The second method for testing
coefficients for significance is the likelihood-ratio test. The likelihood-ratio test uses the
ratio of the maximized value of the likelihood function for the full model (Li) over the
maximized value of the likelihood function for the simpler model (Lo). The likelihood-
ratio test statistic equals:
L
-2log(- L) = - 2 [log(LO) -log(L 1)]= -2(LO - Ll)
This log transformation of the likelihood functions yields a chi-squared statistic. This is
the recommended test statistic to use when building a model through backward stepwise
elimination. The third method for testing coefficients for significance is the Hosmer-
Lemshow goodness of tit test. The Hosmer-Lemshow statistic evaluates the goodness-of-
fit by creating 10 ordered groups of subjects and then compares the number actually in
the each group (observed) to the number predicted by the logistic regression model
(predicted). Thus, the test statistic is a chi-square statistic with a desirable outcome of
non-significance, indicating that the model prediction does not significantly differ from
the observed. The 10 ordered groups are created based on their estimated probability;
those with estimated probability below 0.1 form one group, and so on, up to those with
probability 0.9 to 1.0. Each of these categories is further divided into two groups based
on the actual observed outcome variable (success, failure). The expected frequencies for
each of the cells are obtained from the model. If the model is good, then most of the
subjects with success are classified in the higher deciles of risk and those with failure in
the lower deciles of risk.
StatPlus® software tool was used to perform the logistic regression on Excel.
Chapter 5: Results
A total of forty-five data points were available from the Thomas Reuters Genentech Inc.
oncology dataset. After removing all discovery stage and clinical stage products, sixteen
products were left for the analysis that had either launched or been discontinued. All raw
data can be found in Appendix A.
During the first step of the analysis, three independent variables were removed because
the values were the same for all data points. The variables removed were biomarker for
dose, reimbursement potential, and presence of standard of care. These variables would
not contribute to the regression model or the outcome.
The results of the raw number and normalization analysis led to the elimination of four
more independent variables. These variables were available biomarker for disease
(identified at FDA approval), established endpoints for primary indication, FDA prior
experience with primary indication and type of technology (biologic vs. small molecule).
The threshold for elimination was a delta of less than15%. All variables with a delta of
less than 15% were eliminated from final regression model. All variables with a delta of
greater than or equal to 15% were included in the final regression model. The output of
this analysis is shown in Table 4.
Table 4: Raw Number, Normalization and Delta Calculation for Independent Variables
Established Animal Biomarker Companion Established FDA prior FDA prior Type of Dose-
Mechanism Model for disease Diagnostic Endpoints experience- experience- technology response
of Action disease pathway relationship
Raw
Number
Launched 5 5 2 1 5 5 5 3 2
Failed 8 9 5 4 10 10 6 8 1
Normalized
Launched 100% 100% 40% 20% 100% 100% 100% 60% 40%
Failed 73% 82% 45% 36% 91% 91% 55% 73% 9%
Delta 27% 18% -5% 16% 9% 9% 45% -13% 31%
The logistic regression was performed with the remaining five variables (established
mechanism of action, presence of animal model, companion diagnostic, FDA prior
experience with pathway and dose-response relationship). Output from the logistic
regression can be found in Appendix B.
There were 11 observations of the dependent variable equal to 0, failure, and there were 5
observations of the dependent variable equal to 1, launched.
The chi-square value was 7.738 with the degrees of freedom equal to 5 and with a p-
value of 0.17.
The regression coefficients for each independent variable were as follows:
e Mechanism of action: P = 17.10 with p-value of 0.99
e Animal model: p -16.65 with p-value of 0.99
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- Companion diagnostic: p = -1.79 with p-value of 0.29
- FDA prior experience with pathway: P = 16.65 with p-value of 0.99
- Dose-response relationship: p = 1.94E-14 with p-value of 1.00
Since all p-values are much greater than 0.05, none of these variables directly contribute
to the outcome of launched or failure.
The odds ratio for each independent variable were as follows:
e Mechanism of action: 26,616,199
- Animal model: 0
" Companion diagnostic: 0.1667
- FDA prior experience with pathway: 17,066,840
- Dose-response relationship: 1
These results suggest that the variables mechanism of action and FDA prior
experience with pathway could increase the odds of the outcome (i.e. odds ratio is
greater than 1) when the value of the independent variable is increased by 1 unit.
Chapter 6: Discussion
This analysis was limited by data available for the chosen company. A larger dataset
incorporating multiple companies might have provided a more robust analysis and would
have removed any confounding effects directly linked to the company. Logistic
regression tends to systematically overestimate odds ratios or beta coefficients when the
sample size is less than about 500. With increasing sample size, the magnitude of
overestimation diminishes and the estimated odds ratio asymptotically approaches the
true population value. In a single study, overestimation due to small sample size might
not have any relevance for the interpretation of the results, since it is much lower than the
standard error of the estimate. However, if a number of small studies with systematically
overestimated effects are pooled together without consideration of this effect, an effect
may be perceived when in reality it does not exist. A minimum of 10 events per
independent variable has been recommended4 .
The chi-square value was 7.738 with a p-value of 0.17. The most common assessment of
overall model fit in logistic regression is the goodness-of-fit test (G), which is simply the
chi-square difference between the null model (i.e. with the constant only) and the model
containing the one or more predictors. This is one use of the likelihood ratio test between
two nested models (referred to as "chi-square" in StatPlus binary logistic regression
output). It is an assessment of the improvement of the fit between the predicted and the
observed values on Y by adding the predictors to the model.
Each of the regression coefficients describes the size of the contribution of that risk
factor. A positive regression coefficient means that the explanatory variable increases the
probability of the outcome, while a negative regression coefficient means that the
variable decreases the probability of that outcome; a large regression coefficient means
that the risk factor strongly influences the probability of that outcome, while a near-zero
regression coefficient means that that risk factor has little influence on the probability of
that outcome.
One difficultly with a larger dataset is collecting all of the risk variable information for
each product. Either some the data might not be available or there might be conflicting
evidence that contradicts each other. In both cases, these data points would need to be
excluded from the overall analysis because of the missing inputs.
Other risk variables could have been included in the model. For example, other
regulatory, manufacturing and commercial risks could have been included in the analysis.
These variables might have provided additional insights into predicting success or failure
of products. However, the more variables included, the greater likelihood that some of
those variables are not needed. That is, the variables might not have an effect or they
might be related such that they confound the results.
These types of analyses help to identify the risk factors that play the largest role in the
outcome of a product in drug development. As more evidence become available, the data
might be able to assist in biopharmaceutical portfolio decision making within
biopharmaceutical companies. A major concern with biopharmaceutical companies is
their decreasing levels of productivity and high attrition rates. As we start to better
understand the risks that are involved in drug development and to determine which risks
contribute to the success or failure of a product, then companies can make more informed
decisions in portfolio management. This should lead to companies funding products that
have a higher probability of success of gaining approval from the FDA and being
successful in the market.
Other types of analyses that would augment this logistic regression analysis include
portfolio optimization with specific constraints around the risk factors and qualitative
research with interviews from biopharmaceutical executives. The combination of all of
the analyses could lead to further insights into with risk factors might predict the success
or failure of a biopharmaceutical product.
Additionally, this data, especially combined with other similar analyses, should educate
investors on the risks involved with investing in the life sciences. As investors become
available of the risk and start to understand the risk better, they should be more motivated
to invest. This assumes that a reasonable return is provided.
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Appendix A: Raw Data for Genentech Inc.'s Oncology
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Appendix B: Output from Binary Logistic Regression on StatPlus
Binary Logistic Regression
Summary
VAR Mean Standard Deviation
MOA Dummy (#1) 0.8125 0.39031
Animal Dummy (#2) 0.875 0.33072
Dx Dummy (#3) 0.3125 0.46351
FDA pathway Dummy (#4) 0.6875 0.46351
Dose-Response Dummy (#5) 0.1875 0.39031
Total number of observations
Dependent Variable=0 11
Total number of observations
Dependent Variable= 1 5
Iterations
Null model -2 Log Likelihood 19.87476
Full model -2 Log Likelihood 13.53057
Full model -2 Log Likelihood 12.58242
Full model -2 Log Likelihood 12.29551
Full model -2 Log Likelihood 12.1946
Full model -2 Log Likelihood 12.15801
Full model -2 Log Likelihood 12.14463
Full model -2 Log Likelihood 12.13971
Full model -2 Log Likelihood 12.1379
Full model -2 Log Likelihood 12.13724
Full model -2 Log Likelihood 12.13699
Full model -2 Log Likelihood 12.1369
Full model -2 Log Likelihood 12.13687
Full model -2 Log Likelihood 12.13686
Full model -2 Log Likelihood 12.13685
Process Converged
. . .......... ..  ... ............................. .  ..........   .. ...... .. ......
5 p-level 0.171:
Regression Statistics
VAR Beta Standard Error p-level
MOA Dummy (#1) 17.09703 2,212.64066 0.99383
Animal Dummy (#2) -16.65265 2,965.22533 0.99552
Dx Dummy (#3) -1.79176 1.68325 0.28712
FDA pathway Dummy (#4) 16.65265 1,203.70074 0.98896
Dose-Response Dummy (#5) 1.94471E-14 1.73205 1.
Intercept -16.40388
Odds Ratios
VAR Odds Ratios LCL UCL
MOA Dummy (#1) 26,616,198.92769 0.E+0 #N/A
Animal Dummy (#2) 0. 0.E+0 #N/A
Dx Dummy (#3) 0.16667 0.00615 4.51503
FDA pathway Dummy (#4) 17,066,840.06818 0.E+0 #N/A
Dose-Response Dummy (#5) 1. 0.03355 29.80927
Mechanism of Action Animal Model Companion Dx FDA pathway Dose-Response Dependent Variable
1.
1.
1.
1.
1.
6.37511 E-1 7
1.
6.37511 E-1 7
1.
1.
1.
1.
1.
1.
1.
1.
2.04643E- 17
1.
2.04643E- 17
2.04643E- 17
2.04643E-1 7
2.04643E-1 7
1.
2.04643E-1 7
1.
2.04643E- 17
1.
2.04643E- 17
1.
2.04643E-1 7
2.04643E-1 7
2.04643E-1 7
1.
1.
1.
1.
1.
-2.69966E-1 7
-2.69966E-1 7
-2.69966E-1 7
1.
-2.69966E- 17
1.
-2.69966E- 17
1.
1.
1.
1.
1.
1.04761E-17
1.
1.04761E-17
1.04761E-17
1.04761 E-1 7
1.04761 E-1 7
1.04761E-17
1.04761 E-1 7
1.04761 E-1 7
1.04761E-17
1.04761E-17
1.04761 E-1 7
1.
1.04761 E-1 7
1.04761 E-1 7
1.
1.
1.
1.
1.
0.E+0
0.E+0
0.E+0
0.E+0
0.E+0
0.E+0
0.E+0
0.E+0
0.E+0
0.E+0
0.E+0
p-level
0.666
0.
0.666
0.666
0.666
0.
0.
0.
0.666
0.666
Overall Model Fit
Chi-square 7.73791 Degrees Of Freedom
1.
1.
1.
1.
1.
3.0954E-17
1.
3.0954E-1 7
1.
1.
1.
1.
1.
1.
3.0954E-1 7
1.
Predicted Y
observed 0 1 Total
0 9 2 11
1 1 4 5
Total 10 6 16
